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histochemistry at the dermo±epidermal basement membrane
zone. The initial clinical course was milder, yet the child died at
the age of 10 mo. This pedigree underscores the notion that a
statistical risk of 1.6 3 10±5 is still a practical risk. In this family
screening of the LAMC2 gene of the father for mutations before
initating the pregnancy could have revealed the true risk, 1:4, for
H-JEB.
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Multiple Glomus Tumors of the Skin with Male-to-Male
Transmission Over Four Generations
To the Editor:
Glomus tumors of the skin are benign tumors arising from glomus
bodies or neuromyoarterial receptors that are sensitive to variations
in temperature and regulate arterial ¯ow. The bluish nodules occur
sporadically (mainly as painful solitary tumors on the distal parts of
the extremities) or in a familial pattern (multiple and generally
asymptomatic tumors scattered over the body or localized in a
single area). The inheritance in the few families reported so far has
been autosomal dominant, with some instances of male-to-male
transmission (Tran et al, 1994; Happle and Konig, 1999). In
®ve families, linkage to 1p21-p22, which has been termed
``VMGLOM'' (Boon et al, 1999), was established.
We present a family with a male-to-male transmission over four
generations. All males (n = 14) are affected with glomus tumors of
the angiomatous type (glomangiomas) and all females (n = 10)
remain unaffected (Fig 1). The tumors began to develop at puberty
and involve all parts of the skin except the face, neck, genitals,
palms, and soles. In the 69-y-old index case new lesions are still
developing; in fact, a total of more than 200 have been registered
(Fig 2). The tumors were asymptomatic up to the age of 40 y,
thereafter they started to cause paroxysmal attacks of pain,
aggravated by pressure, trauma, and changes in temperature
(Mullikan and Virnelli-Grevelink, 1999). Histologic examination
of three representative lesions revealed widely dilated vascular
spaces surrounded by ¯at endothelial cells, a ¯at collagen layer, and
clusters of glomus cells containing myo®brils, as seen on electron
Figure 2. Identi®cation of the paternal dele-
tion within intron 3 of LAMC2 in family 2.
(A) Pedigree of families 1 and 2. Heteroduplex of
the PCR products of exon 3 and ¯anking intronic
sequences revealed heteroduplex bands due to the
mutation (see below) in the patient's and his
fathers's DNA (arrow), whereas all other shifts
were polymorphisms. Lane F1, father 1; lane C1,
child 1; lane M1, mother 1; lane F2, father 2; lane
C2, child 2; lane M2, mother 2. (C) Automated
direct sequencing of the PCR product of the
patient's sample showed a 4 bp deletion at posi-
tion +3 adjacent to exon/intron 3 border. (D)
The 521 + 3del4 mutation was con®rmed by re-
striction enzyme digestion. The deletion created a
new restriction site for Mwo I that resulted in di-
gestion of the 315 bp PCR product to 202 bp and
109 bp fragments. Four base points resulting from
an overhang after digestion were not calculated.
The corresponding PCR products representing
maternal DNA and DNA of family 1 remained
undigested. Lane MW, molecular weight markers;
lane F1, C1, M1, F2, C2, M2 as shown above;
lane N, undigested control.
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Figure 1. Pedigree with striking male-to-male transmission. Sym-
bols: s, females, all unaffected; h, males, unaffected, all of them being boys
below the age of 14 y; j, males, affected, ?, died in early childhood, no
other information available.
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microscopy. The tumor cells stained positive for actin, desmin, and
vimentin but negative for pancytokeratin, S100, CD4, CD31,
UEA, and factor VIII. Chromosome analyses from peripheral
lymphocytes of the index case revealed a structurally abnormal Y-
chromosome (paracentric inversion Yq?) and gonosomal aneu-
ploidy: 45,X(1)/46,XY(34)/47,XXY(1)/47,XYY(3). In two me-
taphases a pericentric inversion (12)(p13.3q13) was present. The
breakpoints concern regions of three proto-oncogenes (HST2,
HER3, WNT1). Analyses of Y-speci®c sequences in the genomic
DNA of the patient (SY 14, 70, 78, 85, 132, 156, 160) has revealed
no Y-deletion thus far. Disruption of a gene by the suspected
paracentric inversion Yq cannot be excluded. Further molecular
studies are in progress. Conventional chromosome analyses of one
tumor revealed, in addition to the structurally abnormal Y-
chromosome, a clonal 1; 6 translocation t (1; 6)(q25:q25). Coupling
analyses in the family have not been performed thus far because of
lack of cooperation.
In summary, the presented pedigree is unique as it shows an
exclusive male-to-male transmission of hereditary glomus tumors.
Our ®ndings also suggest a causal involvement of a structurally
abnormal Y-chromosome.
Immunophenotypical characterization of the glomus cells was enabled by Dr. W.
Weninger, Univ.-Dept. of Dermatology, Vienna, Austria.
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Leukaemia Inhibitory Factor (LIF) Expression in Skin from
Amyotrophic Lateral Sclerosis Patients Compared with Skin
from Normal Individuals: What is the Function of LIF in the
Skin?
To the Editor
We read with interest the recent paper by Hu et al (2000)
describing leukaemia inhibitory factor (LIF) expression in the skin
of patients with amyotrophic lateral sclerosis (ALS). To our
surprise, however, the authors recorded no or negligible LIF
immunoreactivity in their ``disease control'' skin (Fig 1, Hu et al,
2000) We also note that they used the skin of patients suffering
from other neurodegenerative disorders as controls for the ALS
patient skin. We do not think these are appropriate controls,
principally because they give the impression that normal undiseased
skin expresses little or no LIF.
Our group has conducted several studies recently on LIF
expression in normal skin and in a variety of in¯ammatory
disorders, using skin from normal individual donors as controls. We
always observed LIF immunoreactivity in normal skin, using the
standard avidin-biotin complex immunohistochemical method.
We have sampled skin from normal individuals both from surgical
patients receiving elective surgery and from punch biopsy of
normal volunteers. In the latter case, samples were dropped
immediately into formalin. In both cases, the results were the same.
A typical result is shown in Fig 1(A), using Fast Red B as
chromogen. Essentially the pattern of LIF staining in normal skin is
the same as reported by Hu et al for ALS skin. The immunostaining
for LIF is always cytoplasmic and was present in the epidermis only.
The lower layers of the epidermis, especially the basal layer, showed
weaker staining compared with the suprabasal epidermis and
corni®ed layers. Similar to Hu et al we found no LIF
immunostaining in the dermis (Fig 1A).
These results on normal skin are consistent and reproducible, not
only in our hands, but French investigators using both polyclonal
and monoclonal antibodies were also able to demonstrate a similar
pattern and intensity of LIF immunoreactivity in normal skin to
that which we had originally recorded.1
Furthermore we have used three different antibodies: rabbit
polyclonal IgG (R303 antibody from the Genetics Institute, Cam-
bridge, MA); rabbit polyclonal IgG (R&D Systems, Minneapolis,
MN), and rabbit polyclonal IgG (UBI, Lake Placid, NY) with the
same results (Paglia et al, 1996; Szepietowski et al, 1997). Our reverse
transcriptase±polymerase chain reaction analysis of normal skin shows
constitutive expression of LIF mRNA, both in vivo and in cultured
human keratinocytes (Paglia et al, 1996; Szepietowski et al, 1997). The
constitutive expression of LIF in normal skin is unusual, since
Figure 2. Multiple glomus tumors presenting as bluish painful
nodules (on the right forearm).
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